East Coast, USA-based biotech firm bluebird bio (Nasdaq: BLUE) has been granted an accelerated assessment by the European regulator for its LentiGlobin gene therapy.
The firm is investigating LentiGlobin as a treatment for certain patients with transfusion-dependent β-thalassemia (TDT), an inherited blood disorder which can lead to serious complications and organ damage.
The expedited status could knock a quarter off the time the European Medicines Agency takes to review a regulatory filing in this indication, down to around five months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze